The global medical landscape is witnessing a surge in advanced immunotherapies, particularly CAR-T cell therapies and bispecific antibodies. While these treatments offer revolutionary outcomes for oncology patients, they often trigger Cytokine Release Syndrome (Crs) Market a systemic inflammatory response that can range from mild flu-like symptoms to life-threatening multi-organ failu... https://shashikant873.livejournal.com/3767.html